PMC:7029759 / 11579-13230
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 265 | 22-31 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 266 | 604-609 | Species | denotes | Ebola | Tax:1570291 |
| 267 | 730-738 | Species | denotes | patients | Tax:9606 |
| 268 | 747-756 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 269 | 917-926 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 270 | 1097-1106 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 271 | 1351-1356 | Species | denotes | mouse | Tax:10090 |
| 272 | 1442-1455 | Species | denotes | coronaviruses | Tax:11118 |
| 273 | 1571-1580 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 274 | 856-859 | Species | denotes | HIV | Tax:12721 |
| 275 | 821-830 | Chemical | denotes | lopinavir | MESH:D061466 |
| 276 | 1257-1267 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 277 | 292-342 | Disease | denotes | immunodeficiency virus (HIV) and hepatitis C virus | MESH:D006526 |
| 278 | 972-976 | Disease | denotes | SARS | MESH:D045169 |
| 279 | 1343-1347 | Disease | denotes | MERS | MESH:D018352 |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T218 | 6-12 | CHEBI:36357;CHEBI:36357 | denotes | agents |
| T217 | 22-31 | SP_7 | denotes | 2019-nCoV |
| T216 | 56-64 | CHEBI:36357;CHEBI:36357 | denotes | molecule |
| T215 | 65-70 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
| T214 | 115-120 | NCBITaxon:10239 | denotes | viral |
| T213 | 121-125 | UBERON:0000104 | denotes | life |
| T212 | 155-166 | GO:0006260 | denotes | replication |
| T211 | 205-210 | NCBITaxon:10239 | denotes | viral |
| T210 | 239-249 | CHEBI:37670;CHEBI:37670 | denotes | inhibitors |
| T209 | 286-291 | SP_6;NCBITaxon:9606 | denotes | human |
| T208 | 309-314 | NCBITaxon:10376 | denotes | virus |
| T207 | 325-334 | NCBITaxon:5690 | denotes | hepatitis |
| T206 | 335-342 | NCBITaxon:10376 | denotes | C virus |
| T205 | 509-514 | NCBITaxon:10239 | denotes | viral |
| T204 | 604-609 | NCBITaxon:10376 | denotes | Ebola |
| T203 | 649-657 | CHEBI:36357;CHEBI:36357 | denotes | molecule |
| T202 | 658-663 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
| T201 | 747-756 | SP_7 | denotes | 2019-nCoV |
| T200 | 821-830 | CHEBI:31781;DG_23;CHEBI:31781 | denotes | lopinavir |
| T199 | 835-844 | DG_30 | denotes | ritonavir |
| T198 | 869-879 | CHEBI:35660;CHEBI:35660 | denotes | inhibitors |
| T197 | 917-926 | SP_7 | denotes | 2019-nCoV |
| T196 | 972-976 | SP_10 | denotes | SARS |
| T195 | 1097-1106 | SP_7 | denotes | 2019-nCoV |
| T194 | 1124-1128 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T193 | 1171-1176 | NCBITaxon:10239 | denotes | virus |
| T192 | 1257-1267 | DG_28 | denotes | remdesivir |
| T191 | 1295-1300 | NCBITaxon:10239 | denotes | viral |
| T190 | 1343-1347 | SP_9 | denotes | MERS |
| T189 | 1351-1356 | NCBITaxon:10088 | denotes | mouse |
| T188 | 1413-1417 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T187 | 1442-1455 | NCBITaxon:11118 | denotes | coronaviruses |
| T186 | 1571-1580 | SP_7 | denotes | 2019-nCoV |
| T185 | 1635-1639 | CHEBI:23888;CHEBI:23888 | denotes | drug |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T59 | 316-319 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
| T60 | 856-859 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
| T61 | 1074-1078 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid_AGAC
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| p4463s12 | 1301-1311 | MPA | denotes | polymerase |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T30 | 292-308 | Disease | denotes | immunodeficiency | http://purl.obolibrary.org/obo/MONDO_0021094 |
| T31 | 325-336 | Disease | denotes | hepatitis C | http://purl.obolibrary.org/obo/MONDO_0005231 |
| T32 | 325-334 | Disease | denotes | hepatitis | http://purl.obolibrary.org/obo/MONDO_0002251 |
| T33 | 604-609 | Disease | denotes | Ebola | http://purl.obolibrary.org/obo/MONDO_0005737 |
| T34 | 972-976 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T101 | 286-291 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T102 | 309-314 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T103 | 337-342 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T104 | 486-489 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T105 | 1074-1078 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T106 | 1122-1123 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T107 | 1171-1176 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T108 | 1316-1319 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T109 | 1351-1356 | http://purl.obolibrary.org/obo/CLO_0007836 | denotes | mouse |
| T110 | 1469-1471 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 34 |
| T111 | 1473-1475 | http://purl.obolibrary.org/obo/CLO_0001000 | denotes | 35 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T32 | 56-64 | Chemical | denotes | molecule | http://purl.obolibrary.org/obo/CHEBI_25367 |
| T33 | 65-70 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T34 | 230-249 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
| T36 | 239-249 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T37 | 349-358 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T38 | 460-469 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T39 | 649-657 | Chemical | denotes | molecule | http://purl.obolibrary.org/obo/CHEBI_25367 |
| T40 | 658-663 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T41 | 821-844 | Chemical | denotes | lopinavir and ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T42 | 821-830 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T43 | 835-844 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T44 | 856-879 | Chemical | denotes | HIV protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_35660 |
| T45 | 860-879 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
| T47 | 869-879 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T48 | 1060-1070 | Chemical | denotes | antivirals | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T49 | 1124-1128 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T50 | 1257-1267 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T51 | 1413-1417 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T52 | 1635-1639 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T6 | 115-131 | http://purl.obolibrary.org/obo/GO_0019058 | denotes | viral life cycle |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T73 | 0-167 | Sentence | denotes | Ideal agents to fight 2019-nCoV would be approved small molecule drugs that could inhibit different aspects of the viral life cycle, ultimately inhibiting replication. |
| T74 | 168-368 | Sentence | denotes | Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens. |
| T75 | 369-480 | Sentence | denotes | Pilot clinical studies are already ensuing by desperate clinicians with various repurposed antiviral medicines. |
| T76 | 481-584 | Sentence | denotes | This has been done in every viral outbreak previously with limited success, outside of case reports 30. |
| T77 | 585-742 | Sentence | denotes | Indeed, during the Ebola outbreak, none of the repurposed small molecule drugs were definitively shown to improve the clinical course across all patients 31. |
| T78 | 743-980 | Sentence | denotes | The 2019-nCoV could be different, and there are initial positive reports that lopinavir and ritonavir, which are HIV protease inhibitors, have some clinical efficacy against 2019-nCoV, similar to prior studies using them against SARS 32. |
| T79 | 981-1225 | Sentence | denotes | Research should continue to be undertaken to screen other clinically available antivirals in cell culture models of 2019-nCoV, in hopes that a drug candidate would emerge useful against the virus that could be rapidly implemented in the clinic. |
| T80 | 1226-1367 | Sentence | denotes | One promising example could be remdesivir, which interferes with the viral polymerase and has shown efficacy against MERS in mouse models 33. |
| T81 | 1368-1476 | Sentence | denotes | For further information, reviews of previous drug repurposing efforts for coronaviruses are provided 34, 35. |
| T82 | 1477-1651 | Sentence | denotes | Though these repurposed medications may hold promise, it is still reasonable to pursue novel, 2019-nCoV specific therapies to complement potential repurposed drug candidates. |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T10 | 292-308 | Phenotype | denotes | immunodeficiency | http://purl.obolibrary.org/obo/HP_0002721 |
| T11 | 325-334 | Phenotype | denotes | hepatitis | http://purl.obolibrary.org/obo/HP_0012115 |